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SUMMARY
Polymyalgia rheumatica (PMR) is one of the most common rheumatic inflammatory disorders in people aged 
over 50. It is characterized by aching and prolonged morning stiffness in the shoulder and pelvic girdles and 
neck. To date there are no specific diagnostic tests, and in clinical practice the diagnosis of PMR remains based 
on its characteristic clinical manifestations, laboratory evidence of systemic inflammation, rapid response to 
low doses of glucocorticoids and exclusion of other disorders that may present with proximal pain and stiffness. 
For classification purposes, several criteria have been proposed over time based on retrospective clinical series, 
but none have been validated and received universal acceptance. Recently, an international collaborative initia-
tive between the EULAR and the ACR was undertaken to develop new polymyalgia rheumatica classification 
criteria. In this review, the provisional 2012 EULAR/ACR classification criteria will be presented and their 
contribution for the diagnosis of polymyalgia rheumatica will be discussed.
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n	 THE NEW 2012 EULAR/ACR 
CLASSIFICATION CRITERIA
Polymyalgia rheumatica (PMR) is an inflammatory disorder of unknown 
cause characterized by aching and pro-
longed morning stiffness in the shoulder, 
pelvic girdles and neck, affecting people 
aged over 50. It is one of the most com-
mon inflammatory rheumatic conditions 
in Caucasian people aged over 50 and its 
incidence increases with advancing age, 
peaking between 70 and 80 years of age. 
A well-known association exists between 
PMR and giant cell arteritis (GCA), a large 
vessel vasculitis that affects the aorta and 
its branches (1). Controversy exists as to 
whether PMR represents a single entity 
disease or is an umbrella term that com-
prises a clinical presentation common to 
a range of related conditions (polymyalgic 
syndrome) (2). To date there are no specific 
diagnostic tests, and in clinical practice 
the diagnosis of PMR remains based on its 
characteristic clinical manifestations, labo-
ratory evidence of systemic inflammation, 
rapid response to low doses of glucocor-
ticoids (GCs) and exclusion of other dis-
orders that may present with polymyalgic 
syndrome (proximal pain and stiffness). 
Ultrasonographic findings of peri-articular 
inflammation lend further support to the di-
agnosis of PMR (3). 
Many features of PMR may predispose the 
unwary clinician to diagnostic error. The 
main symptoms of PMR, such as proxi-
mal pain and stiffness syndrome, systemic 
symptoms, distal musculoskeletal mani-
festation and evidence of systemic inflam-
mation, can occur in many other illnesses. 
Furthermore, the use of a response to GC 
therapy to confirm the diagnosis of PMR 
has several limitations, since GCs are po-
tent anti-inflammatory agents that can 
mask symptoms of other serious condi-
tions, especially if used in high doses and 
for protracted periods. Early differentiation 
between PMR and late onset rheumatoid 
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arthritis (LORA) with PMR-like onset can 
be difficult because these conditions may 
have similar clinical presentation (4). Fol-
low-up is often needed to establish the cor-
rect diagnosis, and in up to 30% of patients 
initially diagnosed as PMR, the disease is 
eventually reclassified as LORA (5).
The International PMR Classification Cri-
teria Group endorsed by ACR and EULAR 
has agreed an approach for the polymy-
algic syndrome that sees the diagnosis of 
PMR as a step-wise process (6, 7):
1. evaluate for core inclusion criteria: age 
over 50; bilateral shoulder and/or pelvic 
girdle aching; morning stiffness dura-
tion longer than 45 min; evidence of an 
acute-phase response;
2. evaluate for exclusion criteria: exclude 
mimicking conditions that cannot coex-
ist with and rule out the diagnosis of 
PMR;
3. evaluate a standardized response to 
GCs (15 mg/day of prednisolone or 
its equivalent): response is defined as 
a patient-reported global improvement 
of 70% within a week of commencing 
GCs and normalization of inflamma-
tory markers within 4 weeks. A lesser 
response should encourage the search 
for an alternative condition;
4. confirmation of the diagnosis on follow-
up: evaluate response to GCs and ex-
clude mimicking conditions during the 
follow-up.
For classification purposes, several crite-
ria have been proposed over time based on 
retrospective clinical series (Table I) (8-
11). However, none of these criteria have 
been validated and received universal ac-
ceptance. Most of these classification cri-
teria include an age cutoff, the presence of 
shoulder and hip girdle pain and morning 
stiffness, duration of symptoms lasting 
more than 2-4 weeks, elevated markers of 
inflammation and the exclusion of other di-
agnoses. Furthermore, some of these clas-
sification criteria include a rapid response 
to GC therapy (9, 11). However, the use of 
a rapid and dramatic response to GC ther-
apy to confirm the diagnosis of PMR has 
limitations. Several recent studies have in-
deed shown that about one third of patients 
with PMR treated with GCs according to a 
standard protocol do not have a complete 
response even after 3 to 4 weeks of treat-
ment (12-14). One of the major unresolved 
issues is the lack of laboratory and/or im-
aging tests that allow early differentiation 
between PMR and other inflammatory 
rheumatic diseases, particularly from RA. 
Regarding this, preliminary studies have 
shown that musculoskeletal ultrasound of 
the shoulders and hips, and antibodies to 
cyclic citrullinated peptides, can differenti-
ate PMR from RA with high specificity and 
acceptable sensitivity (15-18).
The lack of standardized classification 
criteria has been a major factor hamper-
ing the development of rational therapeu-
Table I - Proposed diagnostic criteria for polymyalgia rheumatica.
Chuang et al. (8)
The presence of all these criteria defines PMR diagnosis:
1. Patients 50 years or older
2. Bilateral aching and stiffness persisting for one month or more involving two of 
the following areas: neck or torso, shoulders or proximal regions of the arms, 
and hips or proximal aspects of the thighs
3. Erythrocyte sedimentation rate greater than 40 mm/1st hour
4. Exclusion of other diagnoses except giant cell arteritis
Healey (9)
The diagnosis of PMR is made if all these criteria are satisfied:
1. Persistent pain (for at least one month) involving two of the following areas: 
neck, shoulders, and pelvic girdle
2. Morning stiffness lasting more than 1 h
3. Rapid response to prednisone (20 mg/day or less)
4. Absence of other diseases capable of causing the musculoskeletal symptoms
5. Age over 50 years
6. Erythrocyte sedimentation rate greater than 40 mm/1st hour
Bird et al. (10)
A diagnosis of probable PMR is made if any 3 or more of these criteria are fulfilled:
1. Bilateral shoulder pain and/or stiffness
2. Onset of illness within two weeks
3. Initial erythrocyte sedimentation rate higher than 40 mm/1st hour
4. Morning stiffness exceeding 1 h
5. Age over 65 years
6. Depression and/or loss of weight
7. Bilateral upper arm tenderness
The presence of any 3 or more criteria yields a sensitivity of 92% and a specificity 
of 80%
Jones and Hazleman (11)
Diagnosis of polymyalgia rheumatica requires presence of all the following:
1. Shoulder and pelvic girdle pain, mainly muscular but without muscle weakness
2. Duration of symptoms at least 2 months
3. Morning stiffness
4. ESR >30 mm/h or C-reactive protein >57.14 nmol/L (6 mg/L)
5. Absence of rheumatoid factor, inflammatory arthritis, and malignant disease
6. Absence of objective signs of muscle disease
7. Prompt and pronounced response to glucocorticoids
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tic approaches and causing difficulties in 
evaluating patients in clinical studies. To 
overcome these limitations, an interna-
tional collaborative initiative between the 
EULAR and the ACR was undertaken to 
develop new PMR classification criteria 
(12, 13). These criteria were generated by 
a prospective evaluation of a cohort of 125 
patients with new-onset PMR and 169 sub-
jects aged over 50 with new-onset bilateral 
shoulder pain secondary to conditions po-
tentially mimicking PMR. Musculoskeletal 
ultrasound of the shoulders and hips was 
done in both groups at baseline and at 26 
weeks. The investigators then developed 
a scoring algorithm (Table II) (12, 13). In 
patients aged 50 years or older presenting 
with bilateral shoulder aching and raised 
inflammatory markers (ESR and/or CRP), 
a score of clinical criteria ≥4 had a sensi-
tivity of 68% and specificity of 78% for 
discriminating polymyalgia rheumatica 
from control patients. The specificity was 
higher (88%) for discriminating shoulder 
conditions from PMR and lower (65%) for 
discriminating RA from PMR. The use of 
ultrasound was discretionary; when ultra-
sonography findings consistent with PMR 
were considered, sensitivity decreased 
to 66%, but specificity increased to 81%. 
Again, the specificity was higher (89%) for 
discriminating shoulder conditions from 
PMR and lower (70%) for discriminating 
RA from PMR (12, 13). Therefore, ultra-
sound findings were useful in discriminat-
ing PMR from shoulder conditions, but less 
so in discriminating PMR from RA. How-
ever, ultrasound findings had no effect on 
the sensitivity of the novel EULAR/ACR 
criteria for PMR (12, 13, 19).
To date only two studies have assessed the 
performance of the new 2012 provisional 
EULAR/ACR PMR clinical classification 
criteria in discriminating PMR from other 
mimicking conditions compared with the 
previous published classification criteria, 
reporting conflicting results (20, 21). 
In a single-center retrospective study (20), 
our group compared the performance of 
the published classification/diagnostic cri-
teria for PMR, including the new EULAR/
ACR provisional criteria, in 136 PMR pa-
tients and 149 controls (including 94 with 
rheumatoid arthritis), all prospectively 
followed up according to a standardized 
protocol that included ultrasound examina-
tion of shoulders and hips. The most sen-
sitive criteria were the new EULAR/ACR 
provisional classification criteria (92.6%). 
Adding ultrasound, specificity increased 
from 81.5% to 91.3% when all compara-
tors were considered and from 79.7% to 
89.9% when only rheumatoid arthritis pa-
tients were considered. Bird criteria had a 
sensitivity of 89.2% but the lowest speci-
ficity (40.2% in total cases and 72.5% in 
RA). Jones and Nobunaga criteria were the 
most specific criteria (96.7% and 97.8% in 
total cases and 98.6% and 99.5% in RA) 
but the less sensitive (63.1% and 58.2%). 
Table II - European League Against Rheumatism and American College of Rheumatology provisional cri-
teria for classification of polymyalgia rheumatica.
Required criteria: age 50 years or older, bilateral shoulder aching and abnormal C-reactive protein and/or 
erythrocyte sedimentation rate
Clinical criteria for scoring algorithm:*
1. Morning stiffness lasting more than 45 min 
2. Hip pain or restricted range of motion 
3. Absence of rheumatoid factor and antibody to cyclic citrullinated peptide
4. Absence of other joint involvement 
2 points
1 point
2 points
1 point
Ultrasound criteria for scoring algorithm:*
5a. At least one shoulder with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis; 
and at least one hip with synovitis or trochanteric bursitis 
5b. Both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis 
1 point
1 point
*With only clinical criteria, a score of ≥4 had a sensitivity of 68% and specificity of 78% for discriminating 
polymyalgia rheumatica from comparison patients. With a combination of clinical criteria and ultrasound 
criteria, a score of ≥5 had a sensitivity of 66% and specificity of 81% for discriminating patients with the 
disorder from comparison patients.
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Healey and Chuang criteria had similar 
intermediate sensitivity (80.3% and 77%) 
and specificity (81.5% in total cases and 
78.3% in RA). A more recent prospec-
tive multicenter study assessed the perfor-
mance of the published classification/diag-
nostic criteria for PMR, including the new 
EULAR/ACR provisional criteria, in 275 
patients with new-onset bilateral shoulder 
pain (21). At baseline evaluation, 145 pa-
tients (52.7%) were diagnosed as PMR and 
130 (47.3%) as non-PMR. At the end of 
the 1-year follow-up, 133 patients (48.4%) 
were diagnosed with PMR and 142 (51.6%) 
were diagnosed as non-PMR (including 69 
with RA). The 2012 EULAR/ACR clini-
cal criteria for PMR had a sensitivity of 
89.5% and a specificity of 57.7% when 
tested against all non-PMR cases. Com-
pared with these new classification criteria, 
only the Bird criteria had higher sensitiv-
ity (94%), with lower specificity (50%). 
However, the specificities of the other cri-
teria sets were significantly higher than the 
new 2012 EULAR/ACR clinical criteria, 
ranging from 83%-93%. The Jones crite-
ria and the Chuang criteria had the high-
est specificities (93.7% and 88%, respec-
tively). Surprisingly, when the new 2012 
EULAR/ACR clinical criteria for PMR 
were tested against the 69 RA cases, speci-
ficity increased to 66.7%. Shoulder and hip 
ultrasound were performed only in a sub-
group of 48 patients. With the use of the 
ultrasonography criteria, the sensitivity of 
the 2012 EULAR/ACR criteria increased 
to 91.3% but the specificity decreased to 
52% for discriminating non-PMR condi-
tions from PMR and 53.8% for discrimi-
nating RA from PMR. This unexpected 
finding of Ozen’s study is in disagreement 
with both the original study and the study 
by Macchioni, et al, which showed more 
specificity than sensitivity and a better 
performance when the criteria were used 
to discriminate between PMR and non-
inflammatory shoulder diseases rather than 
between PMR and RA. This observation is 
surprising, because late-onset RA is unani-
mously considered the most challenging 
differential diagnosis. It is difficult to find 
substantial methodological differences be-
tween the three studies that could explain 
the different results obtained. Differences 
in the study design and in the criteria used 
to include patients and controls and the 
clinician’s ability to make a diagnosis and 
perform ultrasonography could, at least in 
part, explain the different results obtained 
(22). Prospective, multicenter studies re-
cruiting a larger number of controls with 
arthritis and other conditions mimicking 
PMR are required. 
In conclusion, PMR is one of the most 
common inflammatory conditions in pa-
tients aged over 50. Various criteria have 
been proposed for the classification of the 
disease, but in clinical practice the diagno-
sis remains only clinical. Imaging modali-
ties may support the clinical diagnosis of 
PMR, and US has been shown to slightly 
improve the specificity of the diagnosis. 
The ACR/EULAR criteria seem to consti-
tute progress in the classification of PMR, 
although they are provisional and need to 
be validated in further prospective studies 
and different settings. Furthermore, these 
criteria are meant for classification and not 
for diagnostic purposes, have not been test-
ed as diagnostic criteria, and can only be 
applied to patients in whom an alternative 
diagnosis responsible for the shoulder pain 
has already been excluded.
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